EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Vir Biotechnology, Inc. (VIR) - What Are Investment Firms Thinking About This Stock?
Hepatitis B Virus (HBV) Infection Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Lab, GSK | ABNewswire
Vir Biotechnology (NASDAQ:VIR) & REGENXBIO (NASDAQ:RGNX) Head-To-Head Survey - Stock Observer
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative? - Simply Wall St News
Could Vir Biotechnology (VIR) Be Above Fair Value After Recent Pipeline News?
I'm Taking Out Some 'Insurance' on My Portfolio With These 2 Stocks
What Could Gilead Sciences (GILD) New Solid Tumor Partnership Mean For Oncology?
Gilead Sciences, Inc. $GILD Stake Trimmed by Curated Wealth Partners LLC - Zolmax
Vir Biotechnology and Gilead Sciences Forge $1.88 Billion Collaboration for Solid Tumor Cancer Therapies, ETPharma
Vir partners with Gilead in $1.8B+ deal for T-cell engagers
Verastem focuses on KRAS G12D therapy, reports 41% ORR in PDAC
Vir Biotechnology Partners With Gilead On Next-Generation Cancer Immunotherapy Programs
Vir Biotechnology Shares Jump on Gilead Cancer Collaboration | Morningstar
Vir CEO sees 'opportunity to do more deals' after striking $1.9B Gilead pact for dual-masked TCEs
Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - What's Next? - Daily Political
Is FDA Fast Track Status Altering The Investment Case For Vir Biotechnology (VIR)?
Is Vir Biotechnology (VIR) Cheap On Fast Track News And SOLSTICE Data Hopes?
Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High - Here's What Happened
Vir Biotechnology (NASDAQ:VIR) Shares Down 6.5% - Time to Sell? - Stock Observer
Vir Biotechnology (NASDAQ:VIR) Shares Climb 6.1% - Here's Why - Stock Observer
Vir Biotechnology (NASDAQ:VIR) Shares Down 6.5% - Here's What Happened
Vir Biotechnology (NASDAQ:VIR) Stock Bumped Down to "Strong Sell" by Zacks Research - Markets Daily
Vir Biotechnology (NASDAQ:VIR) Cut to "Strong Sell" at Zacks Research
How Upcoming SOLSTICE Phase 2 HDV Data Could Shape Vir Biotechnology's (VIR) Investment Narrative
VIR Maintains by HC Wainwright & Co. -- Price Target Raised to $
Vir Biotechnology (NASDAQ:VIR) Given New $22.00 Price Target at HC Wainwright
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026 | Morningstar
Vir Biotechnology (VIR) Could Be 48% Undervalued Following Its CFO Appointment
Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages
